2,187 result(s) found
Ford Will Be A Top Dividend Stock For A Very Long Time
https://seekingalpha.com/article/4660850-ford-will-be-a-top-dividend-stock-for-a-very-long-time?source=feed_all_articles
Jan 02, 2024 - Ford Motor has the potential to become a leader in EV sales. Read why I recommend F stock for growth investors and dividend investors alike.
0
'Big Short' investor Steve Eisman worries 'everybody is coming into the year feeling too good,' sees room for disappointment
https://www.cnbc.com/2024/01/02/big-shorts-steve-eisman-worries-investors-are-too-bullish-in-2024.html
Jan 02, 2024 - Steve Eisman of Neuberger Berman sees little tolerance for things going wrong. He warns the Federal Reserve will likely cut rates fewer times than expected.
0
The 2024 box office is a franchise frenzy — at a time when audiences are feeling IP fatigue
https://www.cnbc.com/2024/01/02/2024-box-office-preview.html
Jan 02, 2024 - The 2024 box office is packed with sequels, prequels and spinoffs, but audiences weren't keen on franchise features in 2023.
0
The New York Times Just Sued Microsoft and OpenAI. Should You Buy the Stock Now?
https://www.fool.com/investing/2024/01/02/the-new-york-times-just-sued-microsoft-and-openai/?source=iedfolrf0000001
Jan 02, 2024 - There could be a a big payoff coming for the media organization.
0
It's time for Minnesota to allow taller buildings with a single staircase
https://www.startribune.com/minnesota-should-allow-taller-residential-buildings-with-a-single-staircase-housing-shortage/600331850/
Jan 02, 2024 -
0
The New York Times Co. (NYT) Flourishes on Subscriber Growth
https://www.zacks.com/stock/news/2204375/the-new-york-times-co-nyt-flourishes-on-subscriber-growth?cid=CS-ZC-FT-analyst_blog|rank_focused-2204375
Jan 02, 2024 - The New York Times Company's (NYT) success story is rooted in its commitment to diversifying revenue sources, optimizing expenses and streamlining operations.
0
Beat the Market the Zacks Way: Shopify, Fusion Pharma, 3M in Focus
https://www.zacks.com/stock/news/2204354/beat-the-market-the-zacks-way-shopify-fusion-pharma-3m-in-focus?cid=CS-ZC-FT-analyst_blog|investment_ideas-2204354
Jan 02, 2024 - Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
0
Time For Small Caps?
https://seekingalpha.com/article/4660662-time-for-small-caps?source=feed_tag_etf_portfolio_strategy
Jan 01, 2024 - Small company stocks have not enjoyed the same level of return that larger company stocks have enjoyed.
0
Revolutionizing Automation: Why UIPath's AI-Powered Technology Is A Smart Investment In 2024
https://seekingalpha.com/article/4660653-uipath-stock-ai-powered-technology-smart-investment-in-2024?source=feed_all_articles
Jan 01, 2024 - UiPath had a significant turnaround in 2023, but PATH stock is still down 70% from its all-time high. Read our bullish thesis here.
0
Intra-Cellular Therapies (ITCI) Now Trades Above Golden Cross: Time to Buy?
https://www.zacks.com/stock/news/2204153/intra-cellular-therapies-itci-now-trades-above-golden-cross-time-to-buy?cid=CS-ZC-FT-tale_of_the_tape|golden_crossover-2204153
Jan 01, 2024 - When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
0